Nurix Therapeutics, Inc. (NRIX) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Nurix (NRIX) PT Raised to $23 at RBC Capital
April 11, 2024 6:28 AM EDTRBC Capital analyst Gregory Renza raised the price target on Nurix (NASDAQ: NRIX) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst comments "The 1Q fiscal 24 EPS report recapped NRIX's recent partnership extensions that expand the company's TPD footprint in the I&I space... More
JPMorgan Takeaways on Nurix (NRIX) Q1 Earnings
April 10, 2024 12:32 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix reported a 1Q loss per share of $0.76, with takeaways from the print being incremental to those from the companys AACR presentation, updated collaboration with SNY, and our recent discussion with mgmt. On NX-5948 (BTK degrader for B-cell malignancies), the... More
